Aurobindo gets USFDA nod to market heart disease drug
NEW DELHI: Aurobindo Pharma has received US health regulator's approval to market Eptifibatide Injection, used in the treatment of acute coronary syndrome, in the American market.
The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Eptifibatide Injection, Aurobindo Pharma said in a filing to the BSE.
This product is expected to be launched in this month, it added.
The Hyderabad-based firm's product is therapeutically equivalent to Schering Corporation's Integrilin injection. Eptifibatide Injection is used in the treatment of acute coronary syndrome.
According to IMS data, the approved product had an estimated market size of USD 137 million for the 12 months ending October 2015.
Aurobindo now has 18 abbreviated new drug application ANDAs approved out of Unit IV formulation facility in Hyderabad.
The company has a total of 222 ANDA approvals, including 10 from Aurolife Pharma LLC and 28 tentative approvals from USFDA.
The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Eptifibatide Injection, Aurobindo Pharma said in a filing to the BSE.
This product is expected to be launched in this month, it added.
The Hyderabad-based firm's product is therapeutically equivalent to Schering Corporation's Integrilin injection. Eptifibatide Injection is used in the treatment of acute coronary syndrome.
According to IMS data, the approved product had an estimated market size of USD 137 million for the 12 months ending October 2015.
Aurobindo now has 18 abbreviated new drug application ANDAs approved out of Unit IV formulation facility in Hyderabad.
The company has a total of 222 ANDA approvals, including 10 from Aurolife Pharma LLC and 28 tentative approvals from USFDA.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.